According to a recent market study published by Growth Market Reports, titled, “Global Mitomycin C Market by type, by application, and by region: Size, Share, Trends and Opportunity Analysis, 2016-2031”, the market was valued at US$ 247.8 Million in 2022 and is anticipated to grow at a growth rate of 2.9% by the year 2031.

Get Sample Report @ https://growthmarketreports.com/request-sample/5357

Mitomycin C (C15H18N4O5) is an antineoplastic antibiotic drug used as a treatment for a number of different types of cancer, such as anal carcinoma, bladder carcinoma, breast carcinoma, and some other gastrointestinal carcinomas. It was first isolated by microbiologists in Japan in the 1950s from cultures of Streptomyces caespitosus.

Mitomycin inhibits DNA synthesis by producing DNA cross-links, which halt cell replication and eventually cause cell death. The cell damage slows or stops the growth of cancer cells in the body. Mitomycin C is given by intravenous infusion, through IV into a vein. The type and schedule are determined by the person's size, type of cancer, and mode of administration.

Mitomycin C is approved by the Food and Drug Administration (FDA) for use in the systemic therapy of metastatic adenocarcinoma of the stomach or pancreas in combination with other drugs.

The Global Mitomycin C Market has been segmented in terms of type, application, and region. In terms of type, the market is split into 2mg, 10 mg, 40 mg, and others. On the basis of application, the market is bifurcated into cancer treatment, ophthalmic use, and others. Considering regions, the market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

The outbreak of coronavirus disease in 2019 (COVID-19) had a slightly negative impact on the global mitomycin C market. Lockdown restrictions as well as delayed cancer screenings, diagnosis, and effective treatment hampered the mitomycin C market. As of April 23, 2023, more than 764 Mn confirmed cases of COVID-19 were reported, and over 6.9 Mn deaths were caused by the disease globally. COVID-19 cases have been registered in more than 223 countries and territories across the globe.

Covid-19 Pandemic delayed cancer screening leading to delayed diagnoses with a high rate of patients diagnosed in an emergency setting. Later-stage cancers with high tumor burden were diagnosed resulting in delayed cancer treatment for patients with newly diagnosed malignancies. Observational data suggest that cancer-specific mortality was higher during the COVID-19 pandemic when compared with pre-pandemic levels. In the US, the number of cancer-related deaths increased by 3% between 2019 which is prior to the pandemic, and 2020 which is during the pandemic. Delays in cancer screening and surveillance during the pandemic impacted the market.

As per growth market reports industry analyst Divyanka Sankhe & Ruchika Sharma, the growing awareness about the effectiveness of mitomycin C in cancer treatment is expected to drive the growth of the market. Mitomycin C is known for its ability to inhabit the growth of cancer cells by interfering with their DNA synthesis. This makes it a valuable tool in cancer treatment.

However, there are some challenges that plays a significant role in hampering the growth of the market such as the side-effects associated with the drug, including nausea, vomiting, and bone marrow suppression. This results in the search for alternative treatments. Overall, the market is expected to grow during the forecast period as mitomycin C gives significant results when used as a combination therapy.

Key Takeaways from the Study

  • The players in the Global Mitomycin C Market include UroGen Pharma, Inc, Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Viatris Inc., Taj Pharma, Laboratorio Varifarma S.A, Accord Healthcare, Inc., Mobius Therapeutics, LLC, Laboratorios Aspen S.A., Meitheal Pharmaceuticals. These hold a major market share of the Global Mitomycin C Market in the year 2022.
  • Demand for mitomycin C as an anti-cancer chemotherapy drug for the treatment of adenocarcinoma of the stomach or pancreas is growing every year. It is also used in the treatment of anal, bladder, breast, cervical, colorectal, head and neck, and non-small cell lung cancer. Colorectal cancer researchers discovered mitomycin C lipidic prodrug (MLP) as an effective treatment for patients suffering from metastasized colorectal carcinoma. 25% of lung tumors activate mutations, resulting in aggressive tumor growth and poor patient prognosis. Researchers have identified mitomycin C as a potential treatment solution in the treatment of lung tumors. Demand for mitomycin C is gradually rising in both breast & bladder cancer treatment, as it is effective in controlling the progression of the disease. Thus, the rising usage of mitomycin C in various cancer treatments is expected to propel the market during the forecast period.
  • Significant investment in R&D activities of cancer research is expected to contribute to the growth of the market during the forecast period. In 2022, global oncology spending accounted for 193 billion USD. National Cancer Institute (NCI) received 216 Mn USD for cancer research from Congress as part of the federal budget. In Jan 2022, Cancer Research UK awarded an 11 Mn USD investment to the University of Oxford and Oxford-based NHS in cancer research for patient benefit. The cancer-drug pipeline and associated investment have been growing substantially. Presently, more than $50 billion is invested in oncology R&D annually. With this investment, the number of active compounds in oncology R&D has quadrupled since 1996 and nearly doubled since 2008 alone. Thus, rising investment in cancer research is expected to create growth opportunities during the forecast period.
  • Based on type, the market is segmented into 2mg, 10 mg, 40 mg, and others. The 40 mg segment is projected to expand at a rapid pace during the forecast period, as it is widely used in the treatment of breast, urinary bladder, and prostate cancer.
  • Based on application, the market is segmented into cancer treatment, ophthalmic use, and others. The cancer treatment segment is projected to expand at a significant pace, as mitomycin C is safe and effective in reducing non-muscle invasive bladder cancer recurrence and progression.
  • In terms of regions, the Global Mitomycin C Markets are divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America holds a significant share of the 40mg segment. The market in the US is projected to continue registering high growth in the coming years, owing to the rising application of mitomycin C in breast & bladder cancer treatment.

Report Scope

Report Metric

Details

Market Value in 2022

US$ 247.8 Million

Market Growth Rate (from 2022 to 2031)

2.9%

Historical Data

2016 & 2021

Base Year

2022

Forecast Period

2023 – 2031

Units Considered

Value (US$ Million)

Market Segments

By Type, By Application, and By Region

Key Companies Profiled

By Type (2mg, 10 mg, 40 mg, and Others), By Application
 (Cancer Treatment, Ophthalmic Use, and Others)

Customization Scope

Report customization available on request

Pricing and Purchase Options

Avail of tailor-made purchase options to meet your research requirements.

Target Audience

  • Supply-side: Manufacturer, Distributors, Stockist.
  • Demand Side: Healthcare
  • Regulatory Side: WHO, FDA, European Medicines Agency, and other approved regulatory bodies.